Soft tissue sarcomas

European Journal of Cancer

Volumn 33, Issue 13, 1997, Pages 2230-2234

  Womer, R B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MOLECULAR BIOLOGY; PATHOGENESIS; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SHORT SURVEY; SOFT TISSUE SARCOMA;

EID: 0031408113     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00334-1     Document Type: Article

References (42)

1. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nature Genetics 1993, 5, 230-235.
2. Davis RJ, D'Cruz CM, Loveli MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1:13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994, 54, 2869-2872.
3. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. Embo Journal 1991, 10, 1135-1147.
4. Shafer BW, CT, Bernasconi M, Genini M, Busslinger M. Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. Nucl Acids Res 1994, 22, 4574-4582.
5. Epstein J, Lam P, Jepeal L, Mass R, Shapiro D. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 1995, 270, 1719-1722.
6. Bernasconi M, Remppis A, Fredericks W, III FR, Shafer B. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Nat Acad Sci U.S.A. 1996, 93, 13164-13169.
7. Chalk J, Worner R, Mitchell C. The genomic breakpoint of the t(2;13) of alveolar rhabdomyosarcoma contains translin recognition sites. Proc Am Assoc Cancer Res 1996, 37, 3814.
8. Barr F. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Ped Hem/Oncol 1997, in press.
9. Zhan S, Shapiro D, Helman L. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994, 94, 445-448.
10. Rodriguez E, Reuter V, Mies C, Bosl G, Chaganti R. Abnormalities of 2q: a common genetic link between rhabdomyosarcoma and hepatoblastoma? Genes, Chromosomes & Cancer 1991, 3, 122-127.
11. Weber-Hall S, Anderson J, McManus A, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 1996, 56, 3220-3224.
12. Asmar L, Gehan E, Newton W, et al. Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Cancer 1994, 74, 2579-2588.
13. Barr FD, Chatten J, D'Cruz CM, et al. Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. J Am Med Assoc 1995, 273, 553-557.
14. Kelly KM, Worner RB, Sorensen P, Xiong Q-B, Barr FG. Translocation subtype predicts clinical behavior in alveolar rhabdomyosarcoma. J Clin Oncol 1997, in press.
15. DeZen L, Sommaggio A, d'Amore E, et al. Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: a retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma Study RMS88. J Clin Oncol 1997, 15, 1198-1205.
16. Niggli FK, Powell JE, Parkes SE, et al. DNA ploidy and proliferative activity (S-phase) in childhood soft-tissue sarcomas: their value as prognostic indicators. Br J Cancer 1994, 69, 1106-1110.
17. Pappo AS, Crist WM, Kuttesch J, et al. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. J Clin Oncol 1993, 11, 1901-1905.
18. Kelly KM, Womer RB, Barr FG. Minimal disease detection in alveolar rhabdomyosarcoma using a reverse transciptase-polymerase chain reaction method. Cancer 1996, 78, 1320-1327.
19. Rodary C, Gehan EA, Flamant F, et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med and Ped Oncol 1991, 19, 89-95.
20. Mandell L, Ghavimi F, LaQuaglia M, Exelby P. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med and Ped Oncol 1990, 18, 466-471.
21. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993, 11, 1911-1918.
22. Pinkerton C. Intensive chemotherapy with stem cell support: Experience in pediatric solid tumours. Bulletin du Cancer 1995, 82 (Suppl. 1), 61s-65s.
23. Womer R. Ifosfamide and paediatrics: should this marriage be saved? Eur J Cancer 1996, 32A, 1100-1101.
24. Miser J, Krailo M, Smith M, et al. Secondary leukemia or myelodysplastic syndrome following therapy for Ewing's sarcoma. Proc Am Soc Clin Oncol 1997, 16, 1863.
25. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 13, 610-630.
26. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987, 5, 1191-1198.
27. Grier H, Krailo M, Link M, et al. Improved outcome in non-metastatic Ewing's sarcoma and PNET of bone with the addition of ifosfamide and etoposide to vincristine, Adriamycin, cyclophosphamide, and actinomycin: a Children's Cancer Group and Pediatric Oncology Group report. Proc Am Soc Clin Oncol 1994, 13, 1443.
28. Arndt C, Womer R, Sloan J, Hawkins D, Miser J. Alternating cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and etoposide/ifosfamide (EI) for the treatment of non-metastatic rhabdomyosarcomas (RMS) and undifferentiated sarcomas (US) of childhood. Proc Am Soc Clin Oncol 1997, 16, 510a.
29. Ruymann F, Crist W, Wiener E, et al. Comparison of two doublet chemotherapy regimens and conventional radiotherapy in metastatic rhabdomyosarcoma: improved overall survival using ifosfamide/etoposide compared to vincristine/melphalan in IRSG-IV. Proc Am Soc Clin Oncol 1997, 16, 1874.
30. Maurer H, Beltangady M, Gehan E, et al. The intergroup rhabdomyosarcoma study-I: a final report. Cancer 1988, 61, 209-220.
31. Rousseau P, Flamant F, Quintana E, Voute P, Gentet J. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study. J Clin Oncol 1994, 12, 516-521.
32. Kingston J, Plowman P, Wright J. Radiotherapy still has a major role in the management of localized orbital rhabdomyosarcoma (letter). J Clin Oncol 1995, 13, 798-799.
33. Atra A, Ward H, Aitken K, et al. Conservative surgery in multi-modal therapy for pelvic rhabdomyosarcoma. Br J Cancer 1994, 70, 1004-1008.
34. Yeung C, Ward H, Ransley P, Duffy P, Pritchard J. Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer 1994, 70, 1000-1003.
35. Lobe T, Wiener E, Andrassay R, et al. The argument for conservative, delayed surgery in the management to prostatic rhabdomyosarcoma. J Ped Surg 1996, 31, 1084-1087.
36. Regine W, Fontanesi J, Kumar P, et al. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients. Int J Rad Oncol Biol and Phys 1995, 31, 485-491.
37. Mandell L, Ghavimi F, Paretz T, LaQuaglia M, Exelby P. Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4000 rad. J Clin Oncol 1990, 8, 1536-1542.
38. Nag S, Olson T, Ruymann F, Teich S, Pieters R. High-dose-rate brachytherapy in childhood sarcomas: a local control strategy preserving bone growth and function. Med and Ped Oncol 1995, 25, 463-469.
39. Wharam M, Anderson J, Breneman J, et al. Radiotherapy for Intergroup Rhabdomyosarcoma Study Clinical Group III patients: influence of primary site on local failure risk. Third International Congress on Soft Tissue Sarcoma in Children and Adolescents. Stuttgart, Germany, 1997, Lecture 11, pp. 1-2.
40. Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diag Molec Path 1995, 4, 162-173.
41. Ladanyi M, Gerard W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumour. Cancer Res 1994, 54, 2837-2840.
42. Kushner B, LaQuaglia M, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996, 14, 1526-1531.